TITLE

EU approves breast cancer drug

AUTHOR(S)
Odriscoll, Cath
PUB. DATE
May 2006
SOURCE
ICIS Chemical Business;5/29/2006, Vol. 1 Issue 21, p41
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the European Union (EU) approval received Roche for using its Herceptin drug for the treatment of the early-stage of breast cancer. This latest ruling widens the scope of the drug, which is already approved in the EU for treating advanced, metastatic, HER2-positive breast cancer, an aggressive form of cancer that affects 20-30% of women with the disease.
ACCESSION #
21297698

 

Related Articles

  • European Oncology Conference.  // BioWorld Today;9/24/2009, Vol. 20 Issue 184, p3 

    The article discusses data of a study on Xeloda, a capecitabine from Roche Holdings AG, against tumors, presented at the European Oncology Conference held in Berlin, Germany. Based on the study, 24 percent of women participants with HER-2-positive or HER2-negative early breast cancer had their...

  • Anything but 'TDM' in San Antonio.  // BioWorld Today;12/15/2009, Vol. 20 Issue 240, p6 

    The article reports on the findings of two studies which investigated the effectiveness of Herceptin (trastuzumab) by Roche Holding AG in treating patients with Human Epidermal growth factor Receptor 2 (HER2)-positive early breast cancer. One of the studies was conducted by the North Central...

  • Roche gains additional EU approval for cancer drug Bondronat.  // PharmaWatch: Cancer;December 2003, Vol. 2 Issue 12, p6 

    Reports that Roche has received in 2003 approval from the European Commission to market its oral biophosphonate drug, Bondronat, for the prevention of skeletal events in patients with breast cancer and bone metastases. Unique position of the oral formulation to fill an unmet patient need for a...

  • Roche's subsidiary wins approval for breast cancer drug in Japan.  // PharmaWatch: Cancer;Apr2008, Vol. 7 Issue 4, p7 

    The article reports on the drug approval granted by the Japanese Health Authority for the use of Herceptin from Chugai Pharmaceutical, a subsidiary of Roche Inc., in treating patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The drug approval was based on the...

  • Genentech/Roche: Avastin back on track.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p7 

    The article reports on the marketing approval issued by the European Union (EU) for the Avastin, a colorectal cancer treatment developed by Genentech Inc. and Roche Pharmaceuticals. The drug has been granted approval in the EU for the first-line treatment of colorectal cancer in combination with...

  • All UK women to be tested for trastuzumab suitability.  // PharmacoEconomics & Outcomes News;10/22/2005, Issue 389, p14 

    Announces the drug trial of the trastuzumab brand Herceptin from Roche on all British women diagnosed with early-stage breast cancer as of October 2005. Disclosure of the intention to quickly approve trastuzumab use by the National Health Service; Use of trastuzumab prior to the test; Comment...

  • Herceptin approval extension.  // Pharmaceutical Technology Europe;Jul2006, Vol. 18 Issue 7, p12 

    The article reports that the U.S. Food and Drug Administration has approved Herceptin or trastuzumab, the controversial breast cancer drug, for use in patients with early stage HER2-positive breast cancer. Approval was granted after the results of the Herceptin Adjuvant study along with three...

  • Genentech/Roche: breast cancer data adds to Avastin's stellar prospects.  // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p7 

    The article presents the author's opinion about the news that Avastin may offer treatment advances in breast cancer. According to the author the news is clearly a major fillip for developers Genentech Inc. and Roche. The developers have revealed that Avastin plus chemotherapy offers improved...

  • Roche preoperative treatment found effective against breast cancer.  // PharmaWatch: Cancer;Feb2008, Vol. 7 Issue 2, p9 

    The article reports on results of a clinical trial initiated by Roche, which suggest that the combination of oral Xeloda and Taxotere may be an active and well-tolerated neoadjuvant treatment option for women with invasive breast cancer. In the multi-center, open-label trial, a majority of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics